162 related articles for article (PubMed ID: 36692972)
1. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
Harris RD; Bernhardt MB; Zobeck MC; Taylor OA; Gramatges MM; Schafer ES; Lupo PJ; Rabin KR; Scheurer ME; Brown AL
Cancer; 2023 Apr; 129(8):1287-1294. PubMed ID: 36692972
[TBL] [Abstract][Full Text] [Related]
2. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
Bhojwani D; Sabin ND; Pei D; Yang JJ; Khan RB; Panetta JC; Krull KR; Inaba H; Rubnitz JE; Metzger ML; Howard SC; Ribeiro RC; Cheng C; Reddick WE; Jeha S; Sandlund JT; Evans WE; Pui CH; Relling MV
J Clin Oncol; 2014 Mar; 32(9):949-59. PubMed ID: 24550419
[TBL] [Abstract][Full Text] [Related]
4. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
[TBL] [Abstract][Full Text] [Related]
5. Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients.
Taylor OA; Brown AL; Brackett J; Dreyer ZE; Moore IK; Mitby P; Hooke MC; Hockenberry MJ; Lupo PJ; Scheurer ME
Clin Cancer Res; 2018 Oct; 24(20):5012-5017. PubMed ID: 30206159
[No Abstract] [Full Text] [Related]
6. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.
Mateos MK; Marshall GM; Barbaro PM; Quinn MCJ; George C; Mayoh C; Sutton R; Revesz T; Giles JE; Barbaric D; Alvaro F; Mechinaud F; Catchpoole D; Lawson JA; Chenevix-Trench G; MacGregor S; Kotecha RS; Dalla-Pozza L; Trahair TN
Haematologica; 2022 Mar; 107(3):635-643. PubMed ID: 33567813
[TBL] [Abstract][Full Text] [Related]
8. CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.
Nathan PC; Maze R; Spiegler B; Greenberg ML; Weitzman S; Hitzler JK
Pediatr Blood Cancer; 2004 Jan; 42(1):24-9. PubMed ID: 14752790
[TBL] [Abstract][Full Text] [Related]
9. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
10. Dextromethorphan Administration on Day 0 and Day 7 for Secondary Prevention of Methotrexate-induced Neurotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Case Series.
Fustino NJ; Juhl K; Leister J
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e284-e287. PubMed ID: 31929386
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
12. Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children.
Dufourg MN; Landman-Parker J; Auclerc MF; Schmitt C; Perel Y; Michel G; Levy P; Couillault G; Gandemer V; Tabone MD; Demeocq F; Vannier JP; Leblanc T; Leverger G; Baruchel A
Leukemia; 2007 Feb; 21(2):238-47. PubMed ID: 17170721
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia.
Shuper A; Stark B; Kornreich L; Cohen IJ; Avrahami G; Yaniv I
Isr Med Assoc J; 2002 Nov; 4(11):1050-3. PubMed ID: 12489505
[TBL] [Abstract][Full Text] [Related]
14. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
15. [Neurotoxicity due to methotrexate in paediatric patients. Description of the clinical symptoms and neuroimaging findings].
Garcia-Puig M; Fons-Estupina MC; Rives-Sola S; Berrueco-Moreno R; Cruz-Martinez O; Campistol J
Rev Neurol; 2012 Jun; 54(12):712-8. PubMed ID: 22673947
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis.
Vagace JM; Caceres-Marzal C; Jimenez M; Casado MS; de Murillo SG; Gervasini G
Am J Hematol; 2011 Jan; 86(1):98-101. PubMed ID: 21064136
[TBL] [Abstract][Full Text] [Related]
17. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia.
Zobeck M; Bernhardt MB; Kamdar KY; Rabin KR; Lupo PJ; Scheurer ME
Pharmacotherapy; 2023 Mar; 43(3):205-214. PubMed ID: 36764694
[TBL] [Abstract][Full Text] [Related]
18. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome.
Rollins N; Winick N; Bash R; Booth T
AJNR Am J Neuroradiol; 2004; 25(10):1688-95. PubMed ID: 15569732
[TBL] [Abstract][Full Text] [Related]
19. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
20. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]